Articles scientifiques

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

Auteurs : André T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ
Année : 2022
Journal : Ann Oncol
Volume : 33
Pages : 1052-1060

CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.

Auteurs : Karam A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H, Kazzi H, Albisinni S, Roumeguère T
Année : 2022
Journal : Cancer Invest
Pages : 1-15

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.

Auteurs : Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, OShaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 72

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Circulating DNA in the neoadjuvant setting of early stage colon cancer.

Auteurs : Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, DHondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F
Année : 2022
Journal : Acta Oncol
Volume : 61
Pages : 1223-1229

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.

Auteurs : Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 87

Polypoid colon mucosa in a leukemia patient.

Auteurs : Lifrange F, Van Gossum A, Verset L, Bron D, Gomez-Galdon M, Demetter P
Année : 2022
Journal : Acta Gastroenterol Belg
Volume : 85
Pages : 118-119

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

Auteurs : Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S
Année : 2022
Journal : J Natl Cancer Inst
Volume : 114(3)
Pages : 467-70

Editorial: Nutrition and the gastrointestinal tract.

Auteurs : Correia MITD, Van Gossum A
Année : 2022
Journal : Curr Opin Clin Nutr Metab Care
Volume : 25
Pages : 319-320

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.

Auteurs : Oosting SF, Barriuso J, Bottomley A, Galotti M, Gyawali B, Kiesewetter B, Latino NJ, Martinelli F, Pe M, Pentheroudakis G, Roitberg F, Vachon H, de Vries EGE, Piccart-Gebhart M, Cherny NI
Année : 2022
Journal : Ann Oncol

First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.

Auteurs : Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E
Année : 2022
Journal : Liver Cancer
Volume : 11
Pages : 268-277

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY

Auteurs : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M
Année : 2022
Journal : Eur J Cancer
Volume : 166
Pages : 219-228

Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.

Auteurs : Goel S, Tan AR, Rugo HS, Aftimos P, Beelen A, Zhang J, Yi JS, Malik R, OShaughnessy J
Année : 2022
Journal : Future Oncol
Volume : 18
Pages : 3701-3711

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.

Auteurs : Awada AH, Boni V, Moreno V, Aftimos P, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Tabernero J
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100651

Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.

Auteurs : Cailleux F, Agostinetto E, Lambertini M, Rothé F, Wu HT, Balcioglu M, Kalashnikova E, Vincent D, Viglietti G, Gombos A, Papagiannis A, Veys I, Awada A, Sethi H, Aleshin A, Larsimont D, Sotiriou C, Venet D, Ignatiadis M
Année : 2022
Journal : JCO Precis Oncol
Volume : 6
Pages : e2200148

Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.

Auteurs : Woff E, Salvatore L, Marmorino F, Genovesi D, Critchi G, Guiot T, Ameye L, Sclafani F, Hendlisz A, Flamen P
Année : 2022
Journal : J Nucl Med
Volume : 63
Pages : 549-555

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

Auteurs : Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, Macpherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM
Année : 2022
Journal : Eur J Cancer
Volume : 164
Pages : 39-51

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Auteurs : Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A
Année : 2022
Journal : J Clin Oncol
Volume : 28
Pages : 3246-3256

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.

Auteurs : Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, Tkint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ
Année : 2022
Journal : Prostate Cancer Prostatic Dis
Volume : 25
Pages : 199-207

The efficacy of the American College of Surgeons Surgical Risk Calculator in the prediction of postoperative complications in oncogeriatric patients after curative surgery for abdominal tumors.

Auteurs : El Asmar A, Hafez K, Fauconnier P, Moreau M, Dal Lago L, Pepersack T, Donckier V, Liberale G
Année : 2022
Journal : J Surg Oncol
Volume : 126
Pages : 1359-1366